1. Search Result
Search Result
Results for "

Glycolic acid

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

2

Natural
Products

3

Isotope-Labeled Compounds

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015967
    Glycolic acid
    1 Publications Verification

    Hydroxyethanoic acid

    Endogenous Metabolite Tyrosinase Metabolic Disease
    Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.
    Glycolic acid
  • HY-W015967S

    Endogenous Metabolite Tyrosinase Metabolic Disease
    Glycolic acid-d2 is the deuterium labeled Glycolic acid. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.
    Glycolic acid-d2
  • HY-22166

    Others Metabolic Disease
    Glycolic acid oxidase inhibitor 1 is a glycolate oxidase inhibitor, extracted from patent EP0021228A1, in Table IV.
    Glycolic acid oxidase inhibitor 1
  • HY-B2247
    PLGA (50:50)
    Maximum Cited Publications
    19 Publications Verification

    poly(lactic-co-Glycolic acid) (50:50)

    Biochemical Assay Reagents Others
    PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.
    PLGA (50:50)
  • HY-B2247A
    PLGA (75:25)
    1 Publications Verification

    poly(lactic-co-Glycolic acid) (75:25)

    Biochemical Assay Reagents Others
    PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .
    PLGA (75:25)
  • HY-B0482

    TVX 1322

    COX Inflammation/Immunology
    Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.
    Acemetacin
  • HY-W015967R

    Hydroxyethanoic acid (Standard)

    Endogenous Metabolite Tyrosinase Metabolic Disease
    Glycolic acid (Standard) is the analytical standard of Glycolic acid. This product is intended for research and analytical applications. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.
    Glycolic acid (Standard)
  • HY-W778203

    Hydroxyethanoic acid-13C2

    Isotope-Labeled Compounds Others
    Glycolic acid- 13C2 is the 13C-labeled Glycolic acid (HY-W015967). Glycolic acid- 13C2 is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.
    Glycolic acid-13C2
  • HY-169373

    E3 Ligase Ligand-Linker Conjugates Others
    Lenalidomide-Glycolic acid is a E3 Ligase Ligand-Linker Conjugate for PROTAC-class FLT3 degrader LWY713 (HY-157213) .
    Lenalidomide-Glycolic acid
  • HY-168726

    PROTAC Linkers Cancer
    Octane-1,8-diamine-Glycolic acid is a PROTAC linker that can be used to synthesize PROTAC molecules (HY-168725) for research in the cancer .
    Octane-1,8-diamine-Glycolic acid
  • HY-B0482R

    COX Inflammation/Immunology
    Acemetacin (Standard) is the analytical standard of Acemetacin. This product is intended for research and analytical applications. Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.
    Acemetacin (Standard)
  • HY-B0482S1

    TVX 1322-13C6

    Isotope-Labeled Compounds COX Inflammation/Immunology
    Acemetacin- 13C6 (TVX 1322- 13C6) is 13C labeled Acemetacin. Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.
    Acemetacin-13C6
  • HY-148775A

    Biochemical Assay Reagents Others
    mPEG-PLGA (21500-26500) is a biodegradable polymer composed of methyl polyethylene glycol (mPEG) and poly(lactic-co-glycolic acid) (PLGA). mPEG-PLGA (21500-26500) can be used in drug delivery systems .
    mPEG-PLGA (21500-26500)
  • HY-158255A

    Biochemical Assay Reagents Others
    mPEG-PLGA (22500-26500) is a biodegradable polymer composed of methyl polyethylene glycol (mPEG) and poly(lactic-co-glycolic acid) (PLGA). mPEG-PLGA (22500-26500) can be used in drug delivery systems .
    mPEG-PLGA (22500-26500)
  • HY-158089

    Biochemical Assay Reagents Others
    PLGA-COOH (MW 80000) (LA/GA 50:50) is a copolymer, which consist of lactic acid (LA)-glycolic acid (GA) with a molar ratio of 50:50, and a carboxyl terminal groups. PLGA-COOH (MW 80000) (LA/GA 50:50) is utilized in drug delivery system for its biocompatibility and biodegradability .
    PLGA-COOH (MW 80000) (LA/GA 50:50)
  • HY-D0153

    Fluorescent Dye Cancer
    Tetramethylrhodamine-5-isothiocyanate is a potent fluorescent dye. Tetramethylrhodamine-5-isothiocyanate can be used for label PG-M3 antibody for rapid diagnosis of acute promyelocytic leukemia (APL). Tetramethylrhodamine-5-isothiocyanate can be used as probe to quantify in vivo the biodistribution of PLGA (poly(lactic-co-glycolic) acid) and PLGA/chitosan nanoparticles .
    Tetramethylrhodamine-5-isothiocyanate
  • HY-157213

    Apoptosis PROTACs FLT3 Cancer
    LWY713 is a PROTAC-class FLT3 degrader (DC50=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).
    LWY713
  • HY-156829

    Biochemical Assay Reagents Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 1:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1)
  • HY-156829A

    Biochemical Assay Reagents Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 15:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1)
  • HY-148775B

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
  • HY-148775

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
  • HY-148776

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)
  • HY-19873

    Photosensitizer Cancer
    SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP)-based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.
    SL-052

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: